**Thermo Fisher's Q2 2026 organic revenue growth faces pressure from ongoing U.S. academic research funding reductions and sluggish life-sciences tools demand, following Q1's 1% organic result.** Management raised full-year 2026 guidance to a 3.5% midpoint after Q1, citing pharma and biopharma investments as offsets, yet analysts highlight limited end-market inflection and conservative consensus revenue estimates near $12 billion (roughly 8% reported growth). Recent reports note academic and government client weakness persisting into 2026, contributing to the market-implied emphasis on sub-2% outcomes ahead of the July 23 earnings release. Trader positioning reflects uncertainty around whether quarterly organic performance will align with the annual path or reflect continued softness in core segments.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено2%-4% 49%
4%+ 49%
-2%-0% 43%
<-2% 40%
НОВЕ
НОВЕ
Jul 23, 2026
<-2%
40%
-2%-0%
43%
0%-2%
28%
2%-4%
49%
4%+
49%
2%-4% 49%
4%+ 49%
-2%-0% 43%
<-2% 40%
НОВЕ
НОВЕ
Jul 23, 2026
<-2%
$20 Обс.
40%
-2%-0%
$20 Обс.
43%
0%-2%
$42 Обс.
28%
2%-4%
$0 Обс.
49%
4%+
$0 Обс.
49%
This market will resolve according to Thermo Fisher's organic revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.**Thermo Fisher's Q2 2026 organic revenue growth faces pressure from ongoing U.S. academic research funding reductions and sluggish life-sciences tools demand, following Q1's 1% organic result.** Management raised full-year 2026 guidance to a 3.5% midpoint after Q1, citing pharma and biopharma investments as offsets, yet analysts highlight limited end-market inflection and conservative consensus revenue estimates near $12 billion (roughly 8% reported growth). Recent reports note academic and government client weakness persisting into 2026, contributing to the market-implied emphasis on sub-2% outcomes ahead of the July 23 earnings release. Trader positioning reflects uncertainty around whether quarterly organic performance will align with the annual path or reflect continued softness in core segments.
This market will resolve according to Thermo Fisher's organic revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Ринок відкрито: Jul 8, 2026, 7:08 PM ET
Обсяг
$82Дата завершення
Jul 23, 2026Ринок відкрито
Jul 8, 2026, 7:08 PM ETResolver
0x69c47De9D...This market will resolve according to Thermo Fisher's organic revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.**Thermo Fisher's Q2 2026 organic revenue growth faces pressure from ongoing U.S. academic research funding reductions and sluggish life-sciences tools demand, following Q1's 1% organic result.** Management raised full-year 2026 guidance to a 3.5% midpoint after Q1, citing pharma and biopharma investments as offsets, yet analysts highlight limited end-market inflection and conservative consensus revenue estimates near $12 billion (roughly 8% reported growth). Recent reports note academic and government client weakness persisting into 2026, contributing to the market-implied emphasis on sub-2% outcomes ahead of the July 23 earnings release. Trader positioning reflects uncertainty around whether quarterly organic performance will align with the annual path or reflect continued softness in core segments.
This market will resolve according to Thermo Fisher's organic revenue growth for the upcoming second fiscal quarter, as reported in its official company earnings materials.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to the lowest bracket.
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to the lowest bracket.
If the reported value falls exactly between two brackets, this market will resolve to the higher range bracket.
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Обсяг
$82Дата завершення
Jul 23, 2026Ринок відкрито
Jul 8, 2026, 7:08 PM ETResolver
0x69c47De9D...**Thermo Fisher's Q2 2026 organic revenue growth faces pressure from ongoing U.S. academic research funding reductions and sluggish life-sciences tools demand, following Q1's 1% organic result.** Management raised full-year 2026 guidance to a 3.5% midpoint after Q1, citing pharma and biopharma investments as offsets, yet analysts highlight limited end-market inflection and conservative consensus revenue estimates near $12 billion (roughly 8% reported growth). Recent reports note academic and government client weakness persisting into 2026, contributing to the market-implied emphasis on sub-2% outcomes ahead of the July 23 earnings release. Trader positioning reflects uncertainty around whether quarterly organic performance will align with the annual path or reflect continued softness in core segments.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання